Used in the treatment of advanced cervical cancer and other solid tumors, this antibody targets the PD-1 receptor on T-cells, blocking its interaction with PD-L1 and PD-L2. This inhibition restores T-cell activity and enhances the immune system’s ability to detect and destroy cancer cells. It is applied in immunotherapy regimens, particularly for patients who have progressed after chemotherapy. Clinical use includes monotherapy or combination with other immune checkpoint inhibitors to improve response rates and prolong survival in certain cancers.